Disc Medicine, Inc.
About Disc Medicine, Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$212.2M
- Total assets
- $806.9M
- Market cap
- $2.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $236.0M
- Operating income
- -$236.0M
- Income tax
- $361.0K
- Net income
- -$212.2M
- EPS (basic)
- $-6.01
- EPS (diluted)
- $-6.01
Balance sheet
- Total assets
- $806.9M
- Current assets
- $803.9M
- Total liabilities
- $67.1M
- Current liabilities
- $36.6M
- Shareholders’ equity
- $739.8M
Cash flow
- Operating cash flow
- -$180.4M
- Investing cash flow
- -$394.3M
- Financing cash flow
- $473.4M
- Net cash flow
- -$101.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.6B
- EPS (diluted)
- $-6.01
- Shares outstanding
- 38.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $212.2M.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Disc Medicine, Inc..
Write a review
News about Disc Medicine, Inc.
News & sentiment via Polygon.io
